Vanguard Group Inc Vaxcyte, Inc. Transaction History

Vanguard Group Inc

$5.57 Trillion
Q4 2024

A detailed history of Vanguard Group Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 11,961,687 shares of PCVX stock, worth $954 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

11,961,687

Previous 11,440,483 4.56%

Holding current value

$954 Million

Previous $1.31 Billion 25.03%

% of portfolio

0.02%

Previous 0.02%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	BUY	$80.97 - $117.93 $42.2 Million - $61.5 Million	521,204 Added 4.56%	11,961,687 $979 Million
Q3 2024 Nov 13, 2024	BUY	$70.52 - $117.12 $116 Million - $192 Million	1,643,488 Added 16.78%	11,440,483 $1.31 Billion
Q2 2024 Aug 13, 2024	BUY	$60.06 - $78.77 $3.59 Million - $4.71 Million	59,741 Added 0.61%	9,796,995 $740 Million
Q1 2024 May 10, 2024	BUY	$59.79 - $81.05 $76.8 Million - $104 Million	1,284,883 Added 15.2%	9,737,254 $665 Million
Q4 2023 Feb 14, 2024	BUY	$45.35 - $63.41 $7.62 Million - $10.7 Million	168,125 Added 2.03%	8,452,371 $531 Million
Q3 2023 Nov 14, 2023	BUY	$46.0 - $53.1 $2.2 Million - $2.54 Million	47,872 Added 0.58%	8,284,246 $422 Million
Q2 2023 Aug 14, 2023	BUY	$34.66 - $54.07 $59.1 Million - $92.1 Million	1,704,058 Added 26.09%	8,236,374 $411 Million
Q1 2023 May 15, 2023	SELL	$36.27 - $47.2 $2.95 Million - $3.84 Million	-81,350 Reduced 1.23%	6,532,316 $245 Million
Q4 2022 Feb 10, 2023	BUY	$20.58 - $47.95 $44.5 Million - $104 Million	2,161,521 Added 48.55%	6,613,666 $317 Million
Q3 2022 Nov 14, 2022	BUY	$21.69 - $28.53 $10.8 Million - $14.2 Million	496,227 Added 12.54%	4,452,145 $107 Million
Q2 2022 Aug 12, 2022	BUY	$17.68 - $26.58 $5.77 Million - $8.68 Million	326,554 Added 9.0%	3,955,918 $86.1 Million
Q1 2022 May 13, 2022	BUY	$17.46 - $26.36 $8.64 Million - $13.1 Million	495,078 Added 15.8%	3,629,364 $87.6 Million
Q4 2021 Feb 14, 2022	BUY	$19.32 - $26.45 $1.75 Million - $2.39 Million	90,404 Added 2.97%	3,134,286 $74.6 Million
Q3 2021 Nov 12, 2021	BUY	$20.26 - $26.97 $3.96 Million - $5.27 Million	195,238 Added 6.85%	3,043,882 $77.2 Million
Q2 2021 Aug 13, 2021	BUY	$16.45 - $24.06 $46.9 Million - $68.5 Million	2,848,644 New	2,848,644 $64.1 Million

Others Institutions Holding PCVX

# of Institutions

349

Shares Held

130M

Call Options Held

539K

Put Options Held

253K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $4.73B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Vaxcyte, Inc. Transaction History